Skin imaging study in eczema patients receiving nemolizumab
Part of Genetic & congenital, Immune system & allergy, Skin clinical trials.
This trial tests whether a special skin imaging technique (reflectance confocal microscopy) can see how nemolizumab changes the skin structure in people with moderate-to-severe eczema. It may help researchers understand how this treatment works.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older.
- You have moderate-to-severe atopic dermatitis (eczema) that your doctor recommends treating with nemolizumab.
- You are willing to try nemolizumab and follow the study procedures.
- You do not have an uncontrolled chronic disease (like diabetes or asthma) that needs steroids.
- You do not have another serious illness that would make it unsafe to participate.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study uses a special microscope to take close-up pictures of your skin before and after starting tralokinumab, a biologic medication for moderate-to-severe eczema (atopic dermatitis). Researchers want to understand how this treatment changes your skin at a microscopic level.
This trial tests an experimental drug called SIM0278 for people with moderate to severe atopic dermatitis (eczema). It aims to see if the drug can reduce skin symptoms and is safe to use.
This study follows adults with moderate to severe eczema who are eligible for or already taking systemic (pill or injection) medicines. It does not test any new drug—it simply tracks how eczema is managed in real life, which may help improve future care.
This study looks at how well nemolizumab works in everyday practice for people with moderate-to-severe atopic dermatitis (eczema). It helps researchers understand the real-world benefits and safety of this treatment.
This trial tests a medicine called nemolizumab for babies aged 6 to 23 months with moderate to severe eczema. The goal is to see if it reduces itching and improves skin symptoms.
This study tests a new injected medication called nemolizumab for people with moderate-to-severe eczema (atopic dermatitis) that hasn't been controlled by creams or ointments. The goal is to see if it reduces symptoms like itching and skin inflammation better than a placebo (inactive shot).
Hear when a new Atopic Dermatitis (Eczema) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.